Neuronal nicotinic receptors in the human brain

Progress in Neurobiology

Volumn 61, Issue 1, 2000, Pages 75-111

  Paterson, David ^a   Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BUNGAROTOXIN; CALCIUM ION; CYTISINE; DIHYDROPYRIDINE; EPIBATIDINE; ION CHANNEL; MESSENGER RNA; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; RADIOLIGAND; RECEPTOR SUBTYPE;

ALZHEIMER DISEASE; ANXIETY NEUROSIS; BINDING SITE; BRAIN DISEASE; COGNITION; DEPRESSION; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HUMAN; LIGAND BINDING; MEMORY; NEUROBLASTOMA CELL; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BRAIN; BRAIN MAPPING; HUMANS; NEURONS; RADIOLIGAND ASSAY; RECEPTORS, NICOTINIC;

EID: 0033964077     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(99)00045-3     Document Type: Review

References (291)

1. Abreo M.A., Lin N.H., Garvey D.S., Gunn D.E., Hettinger A.M., Wasicak J.T., Pavlik P.A., Martin Y.C., Donnelly-roberts D.L., Anderson D.J., Sullivan J.P., Williams M., Arneric S.P., Holladay M.W. Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J. Med. Chem. 39:1996;817-825.
2. Adem A., Synnergren B., Botros M., Ohman B., Winblad B., Nordberg A. [3H] acetylcholine nicotinic recognition sites in human brain: characterization of agonist binding. Neurosci. Lett. 83:1987;298-302.
3. Adem A., Jossan S.S., d'Argy R., Brandt I., Winblad B., Nordberg A. Distribution of nicotinic receptors in human thalamus as visualized by 3H-nicotine and 3H-acetylcholine receptor autoradiography. J. Neural. Transm. 73:1988;77-83.
4. Adem A., Nordberg A., Jossan S.S., Sara V., Gillberg P.G. Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres. Neurosci. Lett. 101:1989;247-252.
5. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry. 150:1993;1856-1861.
6. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry. 32:1992;607-616.
7. Adler L.E., Waldo M.C., Freedman R. Neurophysiologic studies of sensory gating in schizophrenia: comparison of auditory and visual responses. Biol. Psychiatry. 20:1985;1284-1296.
8. Alkondon M., Albuquerque E.X. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. Part I: Pharmacological and functional evidence for distinct structural subtypes. J. Pharmacol. Exp. Ther. 265:1993;1455-1473.
9. Amberla K., Nordberg A., Viitanen M., Winblad B. Long-term treatment with tacrine (THA) in Alzheimer's disease - evaluation of neuropsychological data. Acta. Neurol. Scand. Suppl. 149:1993;55-57.
10. Anand R., Bason L., Saedi M.S., Gerzanich V., Peng X., Lindstrom J. Reporter epitopes: a novel approach to examine transmembrane topology of integral membrane proteins applied to the alpha 1 subunit of the nicotinic acetylcholine receptor. Biochemistry. 32:1993;9975-9984.
11. Anand R., Conroy W.G., Schoepfer R., Whiting P., Lindstrom J. Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J. Biol. Chem. 266:1991;11192-11198.
12. Andrews J.S., Jansen J.H., Linders S., Princen A. Effects of disrupting the cholinergic system on short-term spatial memory in rats. Psychopharmacology (Berl). 115:1994;485-494.
13. Arendash G.W., Sanberg P.R., Sengstock G.J. Nicotine enhances the learning and memory of aged rats. Pharmacol. Biochem. Behav. 52:1995;517-523.
14. 3H ]imipramine in bovine adrenal medullary cells. J. Pharmacol. Exp. Ther. 243:1987;342-348.
15. Arnold S.E., Trojanowski J.Q. Recent advances in defining the neuropathology of schizophrenia. Acta. Neuropathol. (Berl). 92:1996;217-231.
16. Aubert I., Araujo D.M., Cecyre D., Robitaille Y., Gauthier S., Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58:1992;529-541.
17. Balfour D.J., Fagerstrom K.O. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol. Ther. 72:1996;51-81.
18. Bartus R.T., Dean R.L.d., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-414.
19. Beani L., Bianchi C., Nilsson L., Nordberg A., Romanelli L., Sivilotti L. The effect of nicotine and cytisine on 3H-acetylcholine release from cortical slices of guinea-pig brain. Naunyn Schmiedebergs Arch. Pharmacol. 331:1985;293-296.
20. Bednar I., Zhang X., Dastranj-Sedghi R., Nordberg A. Differential changes of nicotinic receptors in the rat brain following ibotenic acid and 192-IgG saporin lesions of the nucleus basalis magnocellularis. Int. J. Dev. Neurosci. 16:1998;661-668.
21. Benowitz N.L. Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 36:1996;597-613.
22. 3H ]nicotine binding sites in human brain. J. Neurochem. 50:1988;1243-1247.
23. Bertrand D., Valera S., Bertrand S., Ballivet M., Rungger D. Steroids inhibit nicotinic acetylcholine receptors. Neuroreport. 2:1991;277-280.
24. Bertrand S., Weiland S., Berkovic S.F., Steinlein O.K., Bertrand D. Properties of neuronal nicotinic acetylcholine receptor mutants from humans suffering from autosomal dominant nocturnal frontal lobe epilepsy. Br. J. Pharmacol. 125:1998;751-760.
25. 3H ]nicotine binding in human postmortem brain. J. Pharmacol. Exp. Ther. 282:1997;7-13.
26. Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav. Genet. 25:1995;95-101.
27. Breslau N., Kilbey M.M., Andreski P. Nicotine dependence and major depression. New evidence from a prospective investigation. Arch. Gen. Psychiatry. 50:1993;31-35.
28. Breslau N., Peterson E.L., Schultz L.R., Chilcoat H.D., Andreski P. Major depression and stages of smoking. A longitudinal investigation. Arch. Gen. Psychiatry. 55:1998;161-166.
29. 3H ]1-nicotine in the mouse brain. Life Sci. 44:1989;1123-1132.
30. Buccafusco J.J., Jackson W.J. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol. Aging. 12:1991;233-238.
31. Buisson B., Gopalakrishnan M., Arneric S.P., Bertrand D. Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: A patch-clump study. J. Neurosci. 16:1996;7880-7891.
32. Caggiula A.R., Donny E.C., Epstein L.H., Sved A.F., Knopf S., Rose C., McAllister C.G., Antelman S.M., Perkins K.A. The role of corticosteroids in nicotine's physiological and behavioral effects. Psychoneuroendocrinology. 23:1998;143-159.
33. Cartaud J., Benedetti E.L., Cohen J.B., Meunier J.C., Changeux J.P. Presence of a lattice structure in membrane fragments rich in nicotinic receptor protein from the electric organ of Torpedo marmorata. FEBS Lett. 33:1973;109-113.
34. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 280:1997;346-356.
35. Chini B., Raimond E., Elgoyhen A.B., Moralli D., Balzaretti M., Heinemann S. Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7). Genomics. 19:1994;379-381.
36. 125I ]-alpha-bungarotoxin. J. Neurosci. 5:1985;1307-1315.
37. Colrain I.M., Mangan G.L., Pellett O.L., Bates T.C. Effects of post-learning smoking on memory consolidation. Psychopharmacology (Berl). 108:1992;448-451.
38. Conroy W.G., Vernallis A.B., Berg D.K. The alpha 5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron. 9:1992;679-691.
39. Cosford N.D., Bleicher L., Herbaut A., McCallum J.S., Vernier J.M., Dawson H., Whitten J.P., Adams P., Chavez-Noriega L., Correa L.D., Crona J.H., Mahaffy L.S., Menzaghi F., Rao T.S., Reid R., Sacaan A.I., Santori E., Stauderman K.A., Whelan K., Lloyd G.K., McDonald I.A. (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB- 1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 39:1996;3235-3237.
40. Court J., Clementi F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis. Assoc. Disord. 9:1995;6-14.
41. Court J.A., Perry E.K., Spurden D., Griffiths M., Kerwin J.M., Morris C.M., Johnson M., Oakley A.E., Birdsall N.J., Clementi F., et al. The role of the cholinergic system in the development of the human cerebellum. Brain Res. Dev. Brain Res. 90:1995;159-167.
42. Couturier S., Bertrand D., Matter J.M., Hernandez M.C., Bertrand S., Millar N., Valera S., Barkas T., Ballivet M. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron. 5:1990;847-856.
43. Covey L.S., Glassman A.H., Stetner F. Major depression following smoking cessation. Am. J. Psychiatry. 154:1997;263-265.
44. Covey L.S., Glassman A.H., Stetner F. Cigarette smoking and major depression. J. Addict Dis. 17:1998;35-46.
45. Coyle J.T., Price D.L., deLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190.
46. Dalack G.W., Glassman A.H., Rivelli S., Covey L., Stetner F. Mood, major depression, and fluoxetine response in cigarette smokers. Am. J. Psychiatry. 152:1995;398-403.
47. Dani J.A., Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron. 16:1996;905-908.
48. Davies P., Feisullin S. Postmortem stability of alpha-bungarotoxin binding sites in mouse and human brain. Brain Res. 216:1981;449-454.
49. de Sarno P., Giacobini E. Modulation of acetylcholine release by nicotinic receptors in the rat brain. J. Neurosci. Res. 22:1989;194-200.
50. Decker M.W. Animal models of cognitive function. Crit. Rev. Neurobiol. 9:1995;321-343.
51. Decker M.W., Brioni J.D., Bannon A.W., Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci. 56:1995;545-570.
52. Decker M.W., Brioni J.D., Sullivan J.P., Buckley M.J., Radek R.J., Raszkiewicz J.L., Kang C.H., Kim D.J., Giardina W.J., Wasicak J.T., et al. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities. Part II: In vivo characterization. J. Pharmacol. Exp. Ther. 270:1994;319-328.
53. Decker M.W., Majchrzak M.J., Anderson D.J. Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res. 572:1992;281-285.
54. Decker M.W., Majchrzak M.J., Arneric S.P. Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol Biochem. Behav. 45:1993;571-576.
55. Delacourte A., Defossez A. Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J. Neurol. Sci. 76:1986;173-186.
56. Dunnett S.B., Martel F.L. Proactive interference effects on short-term memory in rats. Part I: Basic parameters and drug effects. Behav. Neurosci. 104:1990;655-665.
57. Dursun S.M., Reveley M.A. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study. Psychol. Med. 27:1997;483-487.
58. Edwards J.A., Warburton D.M. Smoking, nicotine and electrocortical activity. Pharmacol. Ther. 19:1982;147-164.
59. Eilers H., Schaeffer E., Bickler P.E., Forsayeth J.R. Functional deactivation of the major neuronal nicotinic receptor caused by nicotine and a protein kinase C-dependent mechanism. Mol. Pharmacol. 52:1997;1105-1112.
60. el-Bizri H., Clarke P.B. Regulation of nicotinic receptors in rat brain following quasi-irreversible nicotinic blockade by chlorisondamine and chronic treatment with nicotine. Br. J. Pharmacol. 113:1994;917-925.
61. Elliott K.J., Ellis S.B., Berckhan K.J., Urrutia A., Chavez-Noriega L.E., Johnson E.C., Velicelebi G., Harpold M.M. Comparative structure of human neuronal alpha 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits. J. Mol. Neurosci. 7:1996;217-228.
62. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons Higher than previously reported (see comments). Jama. 262:1989;2551-2556.
63. Fairclough R.H., Josephs R., Richman D.P. Imaging ligand binding sites on the Torpedo acetylcholine receptor. Ann. N Y Acad. Sci. 681:1993;113-125.
64. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41:1992;31-37.
65. 3H ]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J. Neurochem. 47:1986;1948-1954.
66. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA. 94:1997;587-592.
67. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry. 38:1995;22-33.
68. Fryer J.D., Lukas R.J. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J. Neurochem. 72:1999;1117-1124.
69. Fucile S., Matter J.M., Erkman L., Ragozzino D., Barabino B., Grassi F., Alema S., Ballivet M., Eusebi F. The neuronal alpha6 subunit forms functional heteromeric acetylcholine receptors in human transfected cells. Eur. J. Neurosci. 10:1998;172-178.
70. Fuxe K., Janson A.M., Jansson A., Andersson K., Eneroth P., Agnati L.F. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. Naunyn Schmiedebergs Arch. Pharmacol. 341:1990;171-181.
71. Galzi J.L., Changeux J.P. Neuronal nicotinic receptors: molecular organization and regulations. Neuropharmacology. 34:1995;563-582.
72. Gandia L., Villarroya M., Sala F., Reig J.A., Viniegra S., Quintanar J.L., Garcia A.G., Gutierrez L.M. Inhibition of nicotinic receptor-mediated responses in bovine chromaffin cells by diltiazem. Br. J. Pharmacol. 118:1996;1301-1307.
73. Garcia-Colunga J., Awad J.N., Miledi R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA. 94:1997;2041-2044.
74. 18F ]fluoronochloroepibatidine in rodent and human brain. Nucl. Med. Biol. 25:1998;449-454.
75. Gerzanich V., Peng X., Wang F., Wells G., Anand R., Fletcher S., Lindstrom J. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 48:1995;774-782.
76. ++ modulation of human neuronal alpha 3 nicotinic receptors. J. Pharmacol. Exp. Ther. 286:1998;311-320.
77. Glassman A.H., Helzer J.E., Covey L.S., Cottler L.B., Stetner F., Tipp J.E., Johnson J. Smoking, cessation, and major depression (see comments). Jama. 264:1990;1546-1549.
78. Glassman A.H., Stetner F., Walsh B.T., Raizman P.S., Fleiss J.L., Cooper T.B., Covey L.S. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. Jama. 259:1988;2863-2866.
79. Glenner G.G., Wong C.W., Quaranta V., Eanes E.D. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl. Pathol. 2:1984;357-369.
80. Gopalakrishnan M., Buisson B., Touma E., Giordano T., Campbell J.E., Hu I.C., Donnelly-Roberts D., Arneric S.P., Bertrand D., Sullivan J.P. Stable expression and pharmacological properties of the human alpha 7 nicotinic acetylcholine receptor. Eur. J. Pharmacol. 290:1995;237-246.
81. Gopalakrishnan M., Molinari E.J., Sullivan J.P. Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways. Mol. Pharmacol. 52:1997;524-534.
82. Gopalakrishnan M., Monteggia L.M., Anderson D.J., Molinari E.J., Piattoni-Kaplan M., Donnelly-Roberts D., Arneric S.P., Sullivan J.P. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor. J. Pharmacol. Exp. Ther. 276:1996;289-297.
83. 3H ]nicotine binding and differentially regulates mRNA levels of nicotinic acetylcholine receptor subunits expressed in M10 and SH-SY5Y neuroblastoma cells. J. Neurochem. 70:1998;1134-1142.
84. Gotti C., Briscini L., Verderio C., Oortgiesen M., Balestra B., Clementi F. Native nicotinic acetylcholine receptors in human Imr32 neuroblastoma cells: functional, immunological and pharmacological properties. Eur. J. Neurosci. 7:1995;2083-2092.
85. Gotti C., Fornasari D., Clementi F. Human neuronal nicotinic receptors. Prog. Neurobiol. 53:1997;199-237.
86. Gotti C., Wanke E., Sher E., Fornasari D., Cabrini D., Clementi F. Acetylcholine operated ion channel and alpha-bungarotoxin binding site in a human neuroblastoma cell line reside on different molecules. Biochem. Biophys. Res. Commun. 137:1986;1141-1147.
87. Grigoryan G., Hodges H., Mitchell S., Sinden J.D., Gray J.A. 6-OHDA lesions of the nucleus accumbens accentuate memory deficits in animals with lesions to the forebrain cholinergic progection system: effects of nicotine administration on learning and memory in the water maze. Neurobiol. Learn Mem. 65:1996;135-153.
88. Grun E.A., Pauly J.R., Collins A.C. Adrenalectomy reverses chronic injection-induced tolerance to nicotine. Psychopharmacology (Berl). 109:1992;299-304.
89. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA. 83:1986;4913-4917.
90. Grunwald F., Biersack H.J., Kuschinsky W. Nicotine receptor mapping [letter] (see comments). Eur. J. Nucl. Med. 23:1996;1012-1014.
91. 3H ]cytisine binding to human brain membrane preparations. Brain Res. 600:1993;127-133.
92. 11C ]cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET. Int. J. Rad. Appl. Instrum. [B]. 19:1992;871-880.
93. Hatsukami D., Fletcher L., Morgan S., Keenan R., Amble P. The effects of varying cigarette deprivation duration on cognitive and performance tasks. J. Subst. Abuse. 1:1989;407-416.
94. Heimstra N.W., Ellingstad V.S., deKock A.R. Effects of opeator mood on performance in a simulated driving task. Percept. Mot. Skills. 25:1967;729-735.
95. Hellström-Lindahl E., Gorbounova O., Seiger A., Mousavi M., Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Brain Res. Dev. Brain Res. 108:1998;147-160.
96. Hellström-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional distribution of nicotinc receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain (In Process Citation). Brain Res. Mol. Brain Res. 66:1999;94-103.
97. Henningfield J.E. Pharmacologic basis and treatment of cigarette smoking. J. Clin. Psychiatry. 45:1984;24-34.
98. Hennings E.C., Kiss J.P., Vizi E.S. Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices. Brain Res. 759:1997;292-294.
99. Hindmarch I., Kerr J.S., Sherwood N. Effects of nicotine gum on psychomotor performance in smokers and non-smokers. Psychopharmacology (Berl). 100:1990;535-541.
100. Hindmarch I., Sherwood N. Nicotine and cognitive effects. Clarke P.B.S., Quik M., Thurau K. Advances in Pharmacological Sciences. Effects of Nicotine on Biological Systems. Part II. 1995;189-194 Birkhäuser, Verlag, Basel.
101. Horti A., Scheffel U., Stathis M., Finley P., Ravert H.T., London E.D., Dannals R.F. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. J. Nucle. Med. 38:1997;1260-1265.
102. 18F ]Fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors (In Process Citation). Nucl. Med. Biol. 25:1998;599-603.
103. 3H ]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol. Pharmacol. 48:1995;280-287.
104. Hsu Y.N., Amin J., Weiss D.S., Wecker L. Sustained nicotine exposure differentially effecrs alpha 3 beta 2 and alpha 4 beta 2 neuronal nicotinic receptors expressed in Xenopus oocytes. J. Neurochem. 66:1996;667-675.
105. Hsu Y.N., Edwards S.C., Wecker L. Nicotine enhances the cyclic AMP-dependent protein kinase-mediated phosphorylation of alpha 4 subunits of neuronal nicotinic receptors. J. Neurochem. 69:1997;2427-2431.
106. Huganir R.L., Greengard P. Regulation of neurotransmitter receptor desensitization by protein phosphorylation. Neuron. 5:1990;555-567.
107. Inoue M., Kuriyama H. Somatostatin inhibits the nicotinic receptor-activated inward current in guinea pig chromaffin cells. Biochem. Biophys. Res. Commun. 174:1991;750-775.
108. Janson A.M., Fuxe K., Agnati L.F., Jansson A., Bjelke B., Sundstrom E., Andersson K., Harstrand A., Goldstein M., Owman C. Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopamine neurons in the male rat. Prog. Brain Res. 79:1989;257-265.
109. Janson A.M., Fuxe K., Goldstein M. Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin. Investig. 70:1992;232-238.
110. Janson A.M., Fuxe K., Sundstrom E., Agnati L.F., Goldstein M. Chronic nicotine treatment partly protects azgainst the 1-methyl-4-phenyl-2,3,-6tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol. Scand. 132:1988;589-591.
111. Janson A.M., Hedlund P.B., Fuxe K., von Euler G. Chronic nicotine treatment counteracts dopamine D2 receptor upregulation induced by a partial mesodiencephalic hemitransection in the rat. Brain Res. 655:1994;25-32.
112. Janson A.M., Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience. 57:1993;931-941.
113. Jones G.M., Sahakian B.J., Levy R., Warburton D.M., Gray J.A. Effects of acute abcutaneous nicotine on atention, informatkion processing and shortterm memory in Alzheimer's disease. Psychopharmacology (Berl). 180:1992;485-494.
114. Kampfer I., Sorger D., Schliebs R., Karger W., Gunther K., Schulze K., Knapp W.H. Radioiodination of nicotine with specific activity high enough for mapping nicotinic acetylcholine receptors. Eur. J. Nucl. Med. 23:1996;157-162.
115. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., Muller-Hill B. The precursor of Alzeimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325:1987;733-736.
116. Kao P.N., Karlin A. Acetylcholine receptor binding site contains a disulfide cross-link between adjacent half-cystinyl residues. J. Biol. Chem. 261:1986;8085-8088.
117. Karlin A., Akabas M.H. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron. 15:1995;1231-1244.
118. Katz B., Thesleff S. A study of the desensitization produced by acetylcholine at the motor end plate. Journal of Physiology. 138:1957;63-80.
119. 11C ]A-84543: an enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors. Life Sci. 63:1998;PL13-PL18.
120. Ke L., Lukas R.J. Effects of steroid exposure on ligand binding and functiojnal activities of dicerse nicotinic acetylcholine receptor subtypes. J. Neurochem. 67:1996;1100-1112.
121. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann. Neurol. 42:1997;159-163.
122. Kihara T., Shimohama S., Urushitani M., Sawada H., Kimura J., Kume T., Maeda T., Akaike A. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res. 792:1998;331-334.
123. Kim K.D., Lerner-Marmarosh N., Saraswati M., Kende A.S., Abood L.G. 5-Isothiocyanonicotine: a high-affinity irreversible ligand for brain nicotinic receptors. Biochem. Pharmacol. 47:1994;1965-1967.
124. Kowall N.W., Kosik K.S. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease. Ann. Neurol. 22:1987;639-643.
125. Lang W., Henke H. Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of Alzheimer-type patients. Brain Res. 267:1983;271-280.
126. Lange K.W., Wells F.R., Jenner P., Marsden C.D. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J. Neurochem. 60:1993;197-203.
127. Le Houezec J., Halliday R., Benowitz N.L., Callaway E., Naylor H., Herzig K. A low dose of subcutaneous nicotine improves information processing in non-smokers. Psychopharacology (Berl). 114:1994;628-634.
128. Lena C., Changeux J.P. Allosteric modulations of the nicotinic acetylcholine receptor. Trends Neurosci. 16:1993;181-186.
129. Levin E.D. Nicotinic systems and cognitive function. Psychopharmacology (Berl). 108:1992;417-431.
130. Levin E.D., Briggs S.J., Christopher N.C., Rose J.E. Persistence of chronic nicotine-induced cofnitive facilitation. Behav. Neural. Biol. 58:1992;152-158.
131. Levin E.D., Christopher N.C., Briggs S.J., Rose J.E. Chronic nicotine reverse working memory deficits caused by lesions of the fimbria or medial basalocortical projection. Brain Res. Cogn. Brain Res. 1:1993;137-143.
132. Levin E.D., Lee C., Rose J.E., Reyes A., Ellison G., Jarvik M., Gritz E. Chronic nicotine and withdrawal effects on radial-arm maze performance in rats. Behav. Neural. Biol. 53:1990;269-276.
133. Levin E.D., Rose J.E., Abood L. Effects of nicotinic dimethylaminoethyl esters on working memory performance of rats in the radial-arm maze. Pharmacol. Biochem. Behav. 51:1995;369-373.
134. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl). 138:1998;217-230.
135. Levin E.D., Torry D. Acute and chronic nicotine effects on working memory in aged rats. Psychopharmacology (Berl). 123:1996;88-97.
136. Lindström J. Nicotinic acetylcholine receptors in health and disease. Mol. Neurobiol. 15:1997;193-222.
137. Lindström J., Merlie J., Yogeeswarn G. Biochemical properties of acteylcholine receptor subunits from Torpedo californica. Biochemistry. 18:1979;4465-4470.
138. Linville D.G., Arneric S.P. Cortical cerebal blood flow governed by the basal forebrain: age-related impairments. Neurobiol Aging. 12:1991;503-510.
139. Linville D.G., Williams S., Raszkiewicz J.L., Arneric S.P. Nicotinic agonists modulate basal forebrain control of cortica cerbral blood flow in anesthetized rats. J. Pharmacol. Exp. Ther. 267:1993;440-448.
140. Lohr J.B., Flynn K. Smoking and schizophrenia. Schizophr. Res. 8:1992;93-102.
141. London, E.D., 1990. Effects of nicotine on cerebral metabolism. Ciba Found Symp. 152, 131-40, discussion 140-6.
142. 3H ]epibatidine. Eur. J. Pharmacol. 278:1995;R1-R2.
143. Lopez M.G., Fonteriz R.I., Gandia L., de la Fuente M., Villarroya M., Garcia-Sancho J., Garcia A.G. The nicotinic acetylcholine receptor of the bovine chromaffin cell, a new target for dihydropyridines. Eur. J. Pharmacol. 247:1993;199-207.
144. Luetje C.W., Patrick J. Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J. Neurosci. 11:1991;837-845.
145. Lukas R.J. Expression of ganglia-type nicotinic acetylcholine recep tors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line. J. Pharmacol. Exp. Ther. 265:1993;294-302.
146. Lukas R.J., Changeux J.P., le Novere N., Albuquerque E.X., Balfour D.J., Berg D.K., Bertrand D., Chiappinelli V.A., Clarke P.B., Collines A.C., Dani J.A., Grady S.R., Kellar K.J., Lindstrom J.M., Marks M.J., Quik M., Taylor P.W., Wonnacott S. Internatioinal union of pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits (In Process Citation). Pharmacol. Rev. 51:1999;397-401.
147. 11C ]nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain. Alzheimer Dis. Assoc. Disord. 12:1998;238-246.
148. Långström B., Antoni G., Hallidin C., Svärd H., Bergson G. The synthesis of some 11C-labelled alkaloids. Chemica Scripta. 20:1982;40-46.
149. Madhok T.C., Matta S.G., Sharp B.M. Nicotine regulates nicotinic cholinergic receptors and subunit mRNAs in PC 12 cells through protein kinase A. Brain Res. Mol. Brain. Res. 32:1995;143-150.
150. Maelicke A., Schratgenholz A., Storch A., Schroder B., Gutbrod O., Methfessel C., Weber K.H., Pereira E.E., Alkondon M., Albuquerque E.X. Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. J. Recept. Signal Transduct. Res. 15:1995;333-353.
151. Maggio R., Riva M., Vaglini F., Fornai F., Molteni R., Armogida M., Racagni G., Corsini G.U. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem. 71:1998;2439-2446.
152. Maltby N., Broe G.A., Creasey H., Jorm A.F., Christensen H., Brooks W.S. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial (see comments). Bmj. 308:1994;879-883.
153. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Hermans-Borgmeyer I., Heinemann S.F., Collins A.C. Nicotine binding and nicotinic recep tor subunit RNA after chronic nicotine treatment. J. Neurosci. 12:1992;2765-2784.
154. Marks M.J., Romm E., Campbell S.M., Collins A.C. Variation of nicotinic binding sites among inbred strains. Pharmacol. Biochem. Behav. 33:1989;679-689.
155. Marshall D.L., Redfern P.H., Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J. Neurochem. 68:1997;1511-1519.
156. Marutle A., Warpman U., Bogdanovic N., Lannfelt L., Nordberg A. Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amylioid precursor protein 670/671 mutation. J. Neurochem. 72:1999;1161-1169.
157. 3H ]epibatidine (In Process Citation). Brain Res. 801:1998;143-149.
158. Maziere M., Comar D., Marazano C., Berger G. Nicotine-11C: synthesis and distribution kinetics in animals. Eur. J. Nucl. Med. 1:1976;255-258.
159. McConville B.J., Sanberg P.R., Fogelson M.H., King J., Cirino P., Parker K.W., Norman A.B. The effects of nicotine plus haloperidol compared to nictoine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol. Psychiatry. 31:1992;832-840.
160. McGehee D.S., Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57:1995;521-546.
161. Miles K., Greengard P., Huganir R.L. Calcitonin gene-related peptide regulates phosphorylation of the nicotinic acetylcholine receptor in rat myotubes. Neuron. 2:1989;1517-1524.
162. Molinari E.J., Delbono O., Messi M.L., Reganathan M., Arneric S.P., Sullivan J.P., Gopalakrishnan M. Up-regulation of human alpha7 nicotinic
163. Morens D.M., Grandinetti A., Reed D., White L.R., Ross G.W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. 45:1995;1041-1051.
164. Muir J.L., Everitt B.J., Robbins T.W. Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology (Berl). 118:1995;82-92.
165. Mukherjee S., Mahadik S.P., Korenovsky A., Laev H., Schur D.B., Reddy R. Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients. Schizophr. Res. 12:1994;131-136.
166. Mulle C., Lena C., Changeux J.P. Potentiation of nicotinic receptor response by external calcium in rat central neurons. Neuron. 8:1992;937-945.
167. Musachio J.L., Scheffel U., Finley P.A., Zhan Y., Mochizuki T., Wanger H.N. Jr, Dannals R.F. 5-[I-125/123]lodo-3(2(S)-azetidinylmethody)pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. Life Sci. 62:1998;PL351-PL357.
168. 125/123I ]IPH: a radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors. Synapse. 26:1997;392-399.
169. Musachio J.L., Villemagne V.L., Scheffel U.A., Dannals R.F., Dogan A.S., Yokoi F., Wong D.F. Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon (In Process Citation). Nucl. Med. Biol. 26:1999;201-207.
170. Nagata K., Aistrup G.L., Huang C.S., Marszalec W., Song J.H., Yeh J.Z., Narahashi T. Potent modulation of neuronal nicotinic acetylcholine receptor-channel by ethanol. Neurosci. Lett. 217:1996;189-193.
171. Newhouse P.A., Potter A., Corwin J., Lenox R. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharamcology (Berl). 108:1992;480-484.
172. Newhouse P.A., Potter A., Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implicatioins for therapeutics. Drugs Aging. 11:1997;206-228.
173. Newhouse P.A., Potter A., Piasecki M., Geebmuyden J., Corwin J., Lennox R. Nicotinic modulation of cognitive function in humans. Clarke P.B.S., Quik M., Thurau K. Advances in Pharmacological Sciences. Effects of Nicotine on Biological Systems II. 1995;Birkhäuser, Verlag, Basel.
174. Newhouse P.A., Sunderland T., Narang P.K., Mellow A.M., Fertig J.B., Lawlor B.A., Murphy D.L. Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy-volunteers and in patients with Alzheimer's disease. Psychoneruonedocrinology. 15:1990;471-484.
175. Nordberg A. Human nicotinic receptors - their role in aging and dementia. Neurochem. Int. 25:1994;93-97.
176. Nordberg A., Adem A., Hardy J., Winblad B. Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci. Lett. 86:1998;317-321.
177. Nordberg A., Amberla K., Shigeta M., Lundqvist H., Viitanen M., Hellstrom-Lindahl E., Johansson M., Andersson J., Hartvig P., Lilja A., Langstrom B., Winblad B. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerbral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis. Assoc. Disord. 12:1998;228-237.
178. Nordberg A., Hartvig P., Lilja A., Viitanen M., Amberla K., Lundqvist H., Andersson Y., Ulin J., Winblad B., Langstrom B. Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J. Neural. Transm. Park. Dis. Dement. Sect. 2:1990;215-224.
179. Nordberg A., Hartving P., Lundqvist H., Antoni G., Ulin J., Langstrom B. Uptake and regional distribution of (+)-(R)- and (-)-(S)-N-[Methyl-11C]-nicotine in the brains of rhesus monkey. An attempt to study nicotinic receptors in vivo. J. Neural. Transm. Park. Dis. Dement. Sect. 1:1989;195-205.
180. Nordberg A., Lundqvist H., Hartving P., Andersson J., Johansson M., Hellstrom-Lindahi E., Langstrom B. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr. Cogn. Disord. 8:1997;78-84.
181. Nordberg A., Lundqvist H., Hartvig P., Lilja A., Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positorn emission tomography. Alzheimer Dis. Assoc. Disord. 9:1995;21-27.
182. Nordberg A., Nilsoon-Hakansson L., Adem A., Hardy J., Alafuzoff I., Lai Z., Herrera-Marschitz M., Winblad B. The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog. Brain Res. 79:1989;353-362.
183. Nordberg A., Nyberg P., Adolfsson R., Winblad B. Cholinergic topography in Alzheimer brains: a comparison with changes in the monoaminergic profile. J. Neural. Transm. 69:1987;19-32.
184. Nordberg A., Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. 19:1998;465-480.
185. 3H ]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72:1986;115-119.
186. 11C ]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology (Berl). 115:1994;31-36.
187. Nybäck H., Nordberg A., Langstrom B., Halldin C., Hartvig P., Ahlin A., Swahn C.G., Sedvall G. Attempts to visualize nicotinic receptors in the brain of monkey and man by positorn emission tomography. Prog. Brain Res. 79:1989;313-319.
188. Octave J.N. The amyloid peptide and its precursor in Alzheimer's disease. Rev. Neurosci. 6:1995;287-316.
189. Olale F., Gerzanich V., Kuryatov A., Wang F., Lindstrom J. Chronic nicotine exposure differentially addects the function of human alpha3, alpha4, and alpha7 nuronal nicotinic receptor subtypes. J. Pharmacol. Exp. Ther. 283:1997;675-683.
190. Oliverio A. Effects of mecamylamine on avoidance conditioning and maze learning of mice. J. Pharmacol. Exp. Ther. 154:1966;350-356.
191. Orr-Urterger A., Goldner F.M., Saeki M., Lorenzo I., Goldberg L., de Biasi M., Dani J.A., Patrick J.W., Beaudet A.L. Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J. Neurosci. 17:1997;9165-9171.
192. Papke R.L., Duvoisin R.M., Heinemann S.F. The amino terminal half of the nicotinic beta-subunit extracellular domain regulates the kinetics of inhibition by neuronal bungarotoxin. Proc. R. Soc. Lond. B. Biol. Sci. 252:1993;141-148.
193. Papke R.L., Heinemann S.F. The role of the beta 4-subunit in determining the kinetic properties of rat neuronal nicotinic acetylcholine alpha3-receptors. J. Physiol. (Lond). 440:1991;95-112.
194. Pauly J.R., Collins A.C. An autoradiographic analysis of alterations in nicotinic cholinergic receptors following 1 week of corticosterone supplementation. Neuroendocrinology. 57:1993;262-271.
195. Pauly J.R., Marks M.J., Robinson S.F., van de Kamp J.L., Collins A.C. Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha4 or beta2 mRNA levels. J. Pharmacol. Exp. Ther. 278:1996;361-369.
196. Peng X., Gerzanich V., Anand R., Whiting P.J., Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol. Pharmacol. 46:1994;523-530.
197. Pereira E.F., Alkondon M., Reinhardt S., Maelicke A., Peng X., Lindstrom J., Whiting P., Albuquerque E.X. Physostigmine and galanthamine: probes for a novel binding site on the alpha4 beta2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J. Pharmacol. Exp. Ther. 270:1994;768-778.
198. Pereira E.F., Reinhardt-Maelicke S., Schrattenholz A., Maelicke A., Albuquerque E.X. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 265:1993;1474-1491.
199. 3H ]nicotine binding in human cortex: relative abundance in subicular complex. J. Chem. Neuroanat. 5:1992;399-405.
200. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
201. Perry E.K., Tomlinson B.E., Blessed G., Bergmann K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 2:1978;1457-1459.
202. Picciotto M.R., Zoli M., Lena C., Bessis A., Lallemand Y., LeNovere N., Vincent P., Pich E.M., Brulet P., Changeux J.P. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature. 374:1995;65-67.
203. Pich E.M., Pagliusi S.R., Tessari M., Talabot-Ayer D., Hooft van Huijsduijnen R., Chiamulera C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 275:1997;83-86.
204. Pickworth W.B., Herning R.I., Henningfield J.E. Mecamylamine reduces some EEG effects of nicotine chewing gum in humans. Pharmacol. Biochem. Behav. 30:1988;149-153.
205. Pomerleau O.F. Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacol. Bull. 22:1986;865-869.
206. Pontieri F.E., Tanda G., Orzi F., di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs (see comments). Nature. 382:1996;255-257.
207. Pulver A.E., Karayiorgou M., Wolyniec P.S., Lasseter V.K., Kasch L., Nestadt G., Antonarakis S., Housman D., Kazazian H.H., Meyers D., et al. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: Part 1. Am. J. Med. Genet. 54:1994;36-43.
208. Rana B., McMorn S.O., Reeve H.L., Wyatt C.N., Vaughan P.F., Peers C. Inhibition of neuronal nicotinic acetylcholine receptors by imipramine and desipramine. Eur. J. Pharmacol. 250:1993;247-251.
209. Reisine T.D., Yamamura H.I., Bird E.D., Spokes E., Enna S.J. Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res. 159:1978;477-481.
210. Reitstetter R., Lukas R.J., Gruener R. Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J. Pharmacol. Exp. Ther. 289:1999;656-660.
211. Reynolds J.A., Karlin A. Molecular weight in detergent solution of acetylcholine receptor from Torpedo californica. Biochemistry. 17:1978;2035-2038.
212. Risch N. Linkage strategies for genetically complex traits. Part I: Multilocus models (see comments). Am. J. Hum. Genet. 46:1990;222-228.
213. Robinson S.F., Marks M.J., Collins A.C. Inbred mouse strains vary in oral self-selection of nicotine. Psychopharmacology (Berl). 124:1996;332-339.
214. Role L.W., Berg D.K. Nicotinic receptors in the development and modulation of CNS synapses. Neuron. 16:1996;1077-1085.
215. Romanelli L., Ohman B., Adem A., Nordberg A. Subchronic treatment of rats with nicotine: interconversion of nicotinic receptor subtypes in brain. Eur. J. Pharmacol. 148:1988;289-291.
216. Rowell P.P., Duggan D.S. Long-lasting inactivation of nicotinic receptor function in vitro by treatment with high concentrations of nicotine. Neuropharmacology. 37:1998;103-111.
217. Rubboli F., Court J.A., Sala C., Morris C., Chini B., Perry E., Clementi F. Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur. J. Neurosci. 6:1994;1596-1604.
218. Rubboli F., Court J.A., Sala C., Morris C., Perry E., Clementi F. Distribution of neuronal nicotinic receptor subunits in human brain. Neurochem. Int. 25:1994;69-71.
219. Rusted J., Graupner L., O'Connell N., Nicholls C. Does nicotine improve cognitive function? Psychopharmacology (Berl). 115:1994;547-549.
220. Rusted J.M., Warburton D.M. Facilitation of memory by post-trial administration of nicotine: evidence for an attentional explanation. Psychopharmacology (Berl). 108:1992;452-455.
221. Sabbagh M.N., Reid R.T., Corey-Bloom J., Rao T.S., Hansen L.A., Alford M., Masliah E., Adem A., Lloyd G.K., Thal L.J. Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease. J. Neural. Transm. 105:1998;709-717.
222. 125I ] (S)-5-iodonicotine, a new radioiodinated ligand, in the assay of nicotinic acetylcholine receptor binding in the brain. Biol. Pharm. Bull. 18:1995;1463-1466.
223. Salin-Pascual R.J., Drucker-Colin R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport. 9:1998;57-60.
224. Salin-Pascual R.J., Rosas M., Jimenez-Genchi A., Rivera-Meza B.L., Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J. Clin. Psychiatry. 57:1996;387-389.
225. Sanberg P.R., Fogelson H.M., Manderscheid P.Z., Parker K.W., Norman A.B., McConville B.J. Nicotine gum and haloperidol in Tourette's syndrome (letter). Lancet. 1:1988;592.
226. Sanberg P.R., Silver A.A., Shytle R.D., Philipp M.K., Cahill D.W., Fogelson H.M., McConville B.J. Nicotine for the treatment of Tourette's syndrome. Pharmacol. Ther. 74:1997;21-25.
227. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16:1993;403-443.
228. Scheffel U., Taylor G.F., Kepler J.A., Carroll F.I., Kuhar M.J. In vivo labeling of neuronal nicotinic acetylcholine receptors with radiolabeled isomers of norchloroepibatidine. Neuroreport. 6:1995;2483-2488.
229. Scheffer I.E., Bhatia K.P., Lopes-Cendes I., Fish D.R., Marsden C.D., Andermann E., Andermann F., Desbiens R., Keene D., Cendes F., et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain. 118:1995;61-73.
230. Schneider J.S., Pope-Coleman A., van Velson M., Menzaghi F., Lloyd G.K. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov. Disord. 13:1998;637-642.
231. Schneider J.S., van Velson M., Menzaghi F., Lloyd G.K. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann. Neurol. 43:1998;311-317.
232. Schofield G.G., Witkop B., Warnick J.E., Albuquerque E.X. Differentiation of the open and closed states of the ionic channels of nicotinic acetylcholine receptors by tricyclic antidepressants. Proc. Natl. Acad. Sci. USA. 78:1981;5240-5244.
233. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 49:1996;1-6.
234. Schröder H., de Vos R.A., Jansen E.N., Birtsch C., Wevers A., Lobron C., Nowacki S., Schroder R., Maelicke A. Gene expression of the nicotinic acetylcholine receptor alpha4 subunit in the frontal cortex in Parkinson's disease patients. Neurosci. Lett. 187:1995;173-176.
235. 3H ]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J. Neurochem. 45:1985;427-433.
236. Semba J., Mataki C., Yamada S., Nankai M., Toru M. Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats. Biol. Psychiatry. 43:1998;389-391.
237. Sershen H., Hashim A., Lajtha A. behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease. Pharmacol. Biochem. Behav. 28:1987;299-303.
238. Sherwood N. Effects of cigarette smoking on performance in a simulated driving task. Neuropsychobiology. 32:1995;161-165.
239. 3H ]nicotine. J. Neurochem. 45:1985;604-660.
240. Sihver W., Fasth K.J., Ogren M., Bivehed H., Bergstrom M., Nordberg A., Watanabe Y., Langstrom B. In vitro evaluation of 11C-labeled (S)-nicotine, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (R, S)-1-methyl-2-(3-pyridyl)azetidine as nicotinic receptor ligands for positron emission tomography studies. J. Neurochem. 71:1998;1750-1760.
241. 3H ]epibatidine in vitro autoradiography. Neuroscience. 85:1998;1121-1133.
242. Sihver W., Fasth K.J., Horti A.G., Koren A.O., Bergström M., Lu L., Hagberg G., Lundqvist H., Dannals R.F., London E.D., Nordberg A., Langstrom B. Synthesis and characterization of binding of 5-[76Br]bromo-3-[[2(S)-azetidinyl]methoxy] pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. J. Neurochem. 73:1999;1264-1272.
243. Sihver W., Fasth K.J., Ögren M., Lundqvist H., Bergström M., Watanabe Y., Långström B., Nordberg A. In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C] MP compared with [11C] ABT and (S)(-) [11C] nicotine in Rhesus monkeys. Nucl. Med. Biol. 26:1999;633-640.
244. 3H ] epibatidine binding in relation to vesicular acetylcholine transport sites in temporal cortex in Alzheimer's disease. Neuroscience, (in press).
245. Silverman J.M., Greenberg D.A., Altstiel L.D., Siever L.J., Mohs R.C., Smith C.J., Zhou G., Hollander T.E., Yang X.P., Kedache M., Li G., Zaccario M.L., Davis K.L. Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree. Am. J. Med. Genet. 67:1996;162-171.
246. Simmons L.K., Schuetze S.M., Role L.W. Substance P modulates single-channel properties of neuronal nicotinic acetylcholine receptors. Neuron. 4:1990;393-403.
247. Sjöberg S.L., Svensson A.I., Zhang X., Nordberg A. Neuronal nicotinic receptor activation: a promising strategy for treatment of Alzheimer's disease? International Journal of Geriatric Psychopharmacology. 1:1998;145-149.
248. Socci D.J., Sanberg P.R., Arendash G.W. Nicotine enhances Morris water maze performance of young and aged rats. Neurobiol. Aging. 16:1995;857-860.
249. 125I ] alpha-bungarotoxin binding. J. Chem. Neuroanat. 13:1997;105-113.
250. Stage K.B., Glassman A.H., Covey L.S. Depression after smoking cessation: case reports. J. Clin. Psychiatry. 57:1996;467-469.
251. Stauderman K.A., Mahaffy L.S., Akong M., Velicelebi G., Chavez-Noriega L.E., Crona J.H., Johnson E.C., Elliott K.J., Gillespie A., Reid R.T., Adams P., Harpold M.M., Corey-Naeve J. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations alpha2beta4, alpha3beta4 and alpha4beta4 stably expressed in HEK293 cells. J. Pharmacol. Exp. Ther. 284:1998;777-789.
252. Stein E.A., Pankiewicz J., Harsch H.H., Cho J.K., Fuller S.A., Hoffmann R.G., Hawkins M., Rao S.M., Bandettini P.A., Bloom A.S. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am. J. Psychiatry. 155:1998;1009-1015.
253. Steinlein O.K., Mulley J.C., Propping P., Wallace R.H., Phillips H.A., Sutherland G.R., Scheffer I.E., Berkovic S.F. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat. Genet. 11:1995;201-203.
254. Stitzel J.A., Farnham D.A., Collins A.C. Chronic corticosterone treatment elicits dose-dependent changes in mouse brain alpha-bungarotoxin binding. Neuroscience. 72:1996;791-799.
255. Stolerman, I.P. and Jarvis, M.J., 1995. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 117, 2-10, discussion 14-20.
256. Storch A., Schrattenholz A., Cooper J.C., Abdel Ghani E.M., Gutbrod O., Weber K.H., Reinhardt S., Lobron C., Hermsen B., Soskic V., et al. Physostigmine, galanthamine and codeine act as "noncompetitive nicotinic receptor agonists" on clonal rat pheochromocytoma cells. Eur. J. Pharmacol. 290:1995;207-219.
257. Sugaya K., Giacobini E., Chiappinelli V.A. Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J. Neurosci. Res. 27:1990;349-359.
258. Sullivan J.P., Donnelly-Roberts D., Briggs C.A., Anderson D.J., Gopalakrishnan M., Piattoni-Kaplan M., Campbell J.E., McKenna D.G., Molinari E., Hettinger A.M., Garvey D.S., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha4beta2 nicotinic acetylcholine receptor ligand. Neuropharmacology. 35:1996;725-734.
259. Svensson A.L., Nordberg A. Tacrine interacts with an allosteric activator site on alpha4beta2 nAChRs in M10 cells. Neuroreport. 7:1996;2201-2205.
260. Svensson A.L., Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport. 9:1998;1519-1522.
261. Svensson A.L., Warpman U., Hellstrom-Lindahl E., Bogdanovic N., Lannfelt L., Nordberg A. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neurosci. Lett. 232:1997;37-40.
262. Terzano S., Court J.A., Fornasari D., Griffiths M., Spurden D.P., Lloyd S., Perry R.H., Perry E.K., Clementi F. Expression of the alpha3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease. Brain Res. Mol. Brain Res. 63:1998;72-78.
263. Tohgi H., Utsugisawa K., Yoshimura M., Nagane Y., Mihara M. Age-related changes in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in postmortem human frontal cortex and hippocampus. Neurosci. Lett. 245:1998;139-142.
264. Tsuang M.T. Genotypes, phenotypes, and the brain. A search for connections in schizophrenia. Br. J. Psychiatry. 163:1993;299-307.
265. Valenzuela C.F., Dowding A.J., Arias H.R., Johnson D.A. Antibody-induced conformational changes in the Torpedo nicotinic acetylcholine receptor: a fluorescence study. Biochemistry. 33:1994;6586-6594.
266. 11C ]methyl-cytisine. Nucl. Med. Commun. 18:1997;164-168.
267. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J.J., Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61:1993;1828-1834.
268. 125I ]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. Neuroreport. 9:1998;2311-2317.
269. Vidal C. Nicotinic receptors in the brain. Molecular biology, function, and therapeutics. Mol. Chem. Neuropathol. 28:1996;3-11.
270. Villemagne V.L., Horti A., Scheffel U., Ravert H.T., Finley P., Clough D.J., London E.D., Wagner H.N. Jr, Dannals R.F. Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. J. Nucl. Med. 38:1997;1737-1741.
271. Wang F., Gerzanich V., Wells G.B., Anand R., Peng X., Keyser K., Lindstrom J. Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. J. Biol. Chem. 271:1996;17656-17665.
272. Wang S., Sun C.E., Walczak C.A., Ziegle J.S., Kipps B.R., Goldin L.R., Diehl S.R. Evidence for a susceptibility locus for schizophrenia on chromosome 6pter-p22. Nat. Genet. 10:1995;41-46.
273. Warburton D.M., Wesnes K., Shergold K., James M. Facilitation of learning and state dependency with nicotine. Psychopharmacology (Berl). 89:1986;55-59.
274. Warpman U., Friberg L., Gillespie A., Hellstrom-Lindahl E., Zhang X., Nordberg A. Regulation of nicotinic receptor subtypes following chronic nicotinic agonist exposure in M10 and SH-SY5Y neuroblastoma cells. J. Neurochem. 70:1998;2028-2037.
275. Warpman U., Nordberg A. Epibatidine and ABT 418 reveal selective losses of alpha4beta2 nicotinic receptors in Alzheimer brains. Neuroreport. 6:1995;2419-2423.
276. Weiland S., Witzemann V., Villarroel A., Propping P., Steinlein O. An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. FEBS Lett. 398:1996;91-96.
277. Wesnes K., Warburton D.M. Smoking, nicotine and human performance. Pharmacol. Ther. 21:1983;189-208.
278. West R.J., Jarvis M.J. Effects of nicotine on finger tapping rate in non-smokers. Pharmacol. Biochem. Behav. 25:1986;727-731.
279. Wevers A., Jeske A., Lobron C., Birtsch C., Heinemann S., Maelicke A., Schroder R., Schroder H. Cellular distribution of nicotinic acetylcholine receptor subunit mRNAs in the human cerebral cortex as revealed by non-isotopic in situ hybridization. Brain Res. Mol. Brain Res. 25:1994;122-128.
280. Whitehouse P.J., Au K.S. Cholinergic receptors in aging and Alzheimer's disease. Prog. Neuropsychopharmacol Biol. Psychiatry. 10:1986;665-676.
281. Whitehouse P.J., Hedreen J.C., White C.L.d., Price D.L. Basal forebrain neurons in the dementia of Parkinson disease. Ann. Neurol. 13:1983;243-248.
282. Whitehouse P.J., Martino A.M., Antuono P.G., Lowenstein P.R., Coyle J.T., Price D.L., Kellar K.J. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 371:1986;146-151.
283. 3H ]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology. 38:1988;720-723.
284. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.
285. Whiting P., Esch F., Shimasaki S., Lindstrom J. Neuronal nicotinic acetylcholine receptor beta-subunit is coded for by the cDNA clone alpha4. FEBS Lett. 219:1987;459-463.
286. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 20:1997;92-98.
287. Wonnacott, S., Drasdo, A., Sanderson, E., Rowell, P., 1990. Presynaptic nicotinic receptors and the modulation of transmitter release. Ciba Found Symp 152, 87-101, discussion 102-5.
288. Zamani M.R., Allen Y.S., Owen G.P., Gray J.A. Nicotine modulates the neurotoxic effect of beta-amyloid protein(25-35)) in hippocampal cultures. Neuroreport. 8:1997;513-517.
289. Zhang X., Gong Z.H., Fasth K.J., Langstrom B., Nordberg A. Interaction of the nicotinic agonist (R, S)-3-pyridyl-1-methyl-2-(3- pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex. Neurochem. Int. 32:1998;435-441.
290. Zoli M., Le Novere N., Hill J.A. Jr, Changeux J.P. Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J. Neurosci. 15:1995;1912-1939.
291. Zoli M., Lena C., Picciotto M.R., Changeux J.P. Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J. Neurosci. 18:1998;4461-4472.